Consistent efficacy of B/F/TAF in treatment-naïve HIV patients across different baseline HIV-1 RNA levels at week 48

• Published in: Chinese medical journal Vol. 136; no. 22; pp. 2747 - 2749
• Main Authors: He, Kun, Zhou, Yihong, Yang, Honghong, Lu, Yanqiu, Tan, Qiuxiang, Qi, Weiwei, Liu, Min
• Format: Journal Article
• Language: English
• Published: Baltimore Lippincott Williams & Wilkins Ovid Technologies 20.11.2023; Lippincott Williams & Wilkins; Wolters Kluwer
• Subjects: Correspondence; Drug resistance; HIV; Human immunodeficiency virus; Mutation; Patients; Review boards; United States > US
• ISSN: 0366-6999; 2542-5641
• DOI: 10.1097/CM9.0000000000002887

In Chongqing, China, where the prevalence of advanced HIV among hospitalized patients living with HIV exceeds 70%,[2] up to 25% of patients have baseline HIV-1 RNA >500,000 copies/mL in our study, and many patients have opportunistic infections. [...]we conducted this real-world retrospective study to gain a more comprehensive understanding of the efficacy and safety of B/F/TAF. The study received approval from the Institutional Review Board of Chongqing Public Health Medical Center (CPHMC) (No. 2023-020-02-KY). Since this study was retrospective and all patient data were analyzed anonymously, the institutional review board waived the requirement for written informed consent. In the multivariate analysis, baseline total bilirubin level >17.1 μmol/L (OR = 8.609, 95% confidence interval [CI]: 2.363–31.364), baseline HIV-1 RNA 100,000–500,000 copies/mL (OR = 6.517, 95% CI: 1.203–35.300), and baseline HIV-1 RNA >500,000 copies/mL (OR = 20.045, 95% CI: 3.753–107.062) were identified as independent risks of HIV-1 RNA ≥50 copies/mL within w24 [Supplementary Table 2, http://links.lww.com/CM9/B807]. High-density lipoprotein cholesterol (HDL-c) levels improved from 0.95 (IQR 0.79–1.12) mmol/L to 1.27 (IQR 1.09–1.45) mmol/L (P <0.05) during the first 24-week follow-up period and remained stable from w24 to w48.